Many countries have already manufactured vaccines in a large amount, but whether the vaccine is effective or got approved became huge questions. Pfizer became one of the first manufacturers of COVID-19, followed by India’s Serum Institute. However, now many have joined the brigade. Johnson’s & Johnson’s vaccine is now on the go, and FDA advisers are backing the vaccine.
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend EUA of the vaccine in people 18 and older. They are working towards the finalization and issuance of an emergency use authorization for Johnson’s & Johnson’s. The approval of the emergency use will help with vaccine allocation and distribution. The plan for timely vaccine distribution will be easily achieved if the vaccine is approved.
Johnson’s & Johnson’s will be the third vaccine to be authorized for use in the United States. This vaccine is better than Pfizer and Moderna vaccine because it is a one-shot vaccine. Moreover, it can be stored in regular refrigerators, making it easier to distribute.
The vaccine called Janssen was tested in advanced clinical trials in more than 44,000 people in the US, South Africa, and Latin America. The results showed that it showed an overall efficacy of 66% in preventing moderate-to-severe disease, globally. However, In the US, this efficacy was higher – 72% and it was 85% effective in preventing severe disease.
The Johnson’s & Johnson’s vaccine will change the way people are getting vaccinated. Usually, most of the Vaccines around the world required 2 shots, however, this version of the vaccine seems to be better and improved.